McDermott Will & Schulte advises Sagard NewGen on its investment in Quipment | McDermott Skip to main content

McDermott Will & Schulte advises Sagard NewGen on its investment in Quipment

McDermott Will & Schulte advises Sagard NewGen on its investment in Quipment

Überblick


McDermott Will & Schulte advised Sagard NewGen on its minority investment in Quipment, a leading provider of equipment solutions for clinical trials, alongside its founders and management team.

This strategic investment will strengthen the company’s position as a global partner to CROs and sponsors.

The McDermott team comprised:

Über uns


Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.